TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: First Needle Puncture Success Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cannulation Success Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-to-clinical improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Follicle stimulating hormone (FSH) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cognitive speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concurrent measurement validity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Criterion-related validity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Latency to first epileptic seizure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of knowledge and practices regarding modern FP methods
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of pregnancy related complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with proper knowledge about skilled MNCH services
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of recently delivered women utilizing skilled ANC, DC, and PNC services
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Participant completion of study protocol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Severe postoperative morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Malaria transmission rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: EyeSimplify Self-Test Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: EyeSimplify Self-Test Persistence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants for Which Intervillous Placental Blood is Detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of Participant for Which Placental Lesions Are Detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of Participants for Which Macrophage at the Implementation Site Are Detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rapid error rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Innocell in Ovarian Cancer Patients
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity of Innocell in Ovarian Cancer Patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Recruitment rate estimation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Retention rate estimation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of the intervention - VAS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes from baseline in clinical safety laboratory values and vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical consequences associated with medication errors
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Abnormal Physical Examination Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Abnormal Serum Chemistries and Hematology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acquisition rate of the core tissue sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of postoperative respiratory failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety and tolerability of LT-002-158
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of disease treatments
Endpoint domain: Adverse events/effects
Primary endpoint: Discontinuation of low-dose LNG-IUS
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Competition rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in International Index of Erectile Function (IIEF) questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change of GH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of pituitary prolactin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of ACTH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of FSH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of thyroid hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Derivation rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: [177Lu]Lu DOTA-ABM-5G treatment efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue distribution of 18F-RD2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence of eumycetoma lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Compliance rate of infection control practices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Average Chest compression depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average chest compression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of chest recoil
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in CooC11 (perceived cooking competence) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in perceived motor competence score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Stirling Children's Wellbeing Scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: quantitative parameters by MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No detectable damage in biopsy samples
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of gastroesophageal reflux disease symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Adapted Patient Clinical Global Impression of Improvement (CGI-I) scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Health Literacy Questionnaire (HLQ) Score for Feeling Understood by Healthcare Providers Subscale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Health Literacy Questionnaire (HLQ) Score for Having Sufficient Information Subscale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Health Literacy Questionnaire (HLQ) Score for Actively Managing Health Subscale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decisional Conflict Scale (DCS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in frequency of prescription stimulant diversion
Endpoint domain: Adverse events/effects
Primary endpoint: Change in intention to divert prescription stimulant medication
Endpoint domain: Adverse events/effects
Primary endpoint: Change in frequency of prescription stimulant medication misuse
Endpoint domain: Adverse events/effects
Primary endpoint: d_MBP(awake)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: d_MBP(GA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child anxiety scale-state
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: The Faces Pain Scale - Revised
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve (AUC0-24hrs) of Enlicitide Decanoate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve (AUC0-24hrs) of Semaglutide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Semaglutide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Plasma Concentration (Tmax) of Enlicitide Decanoate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: one year disease-free survival (DFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Diagnosis of Delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 2-year seizure free survival
Endpoint domain: Mortality/survival
Primary endpoint: Personal Financial Wellness
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Cardiac death or heart transplantation
Endpoint domain: Mortality/survival
Primary endpoint: Neural networks associated with chronic tinnitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Localized or systemic safety events
Endpoint domain: Adverse events/effects
Primary endpoint: SARS CoV-2 infection severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of non-hematologic grade ≥3 treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Secure firearm storage practices
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Proportion of scheduled appointment no-show rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Level of Neutrophil gelatinase-associated lipocalin (NGAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of Dickkopf-3 (DKK3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of family centered care rated by parents
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hunger perception before and after test meals consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initiation of lipid-lowering therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Progression-free Survival Rate at 12 months (rPFS12)
Endpoint domain: Mortality/survival
Primary endpoint: Adverse Events Related to Device
Endpoint domain: Adverse events/effects
Primary endpoint: WOMAC assessment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of eligible dyads who enroll
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of participants who return for a second session
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Boston Bowel preparation scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of adequately prepared patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: time to death from any cause
Endpoint domain: Mortality/survival
Primary endpoint: Sustained objective response rate in recurrent/progressive previously irradiated ACP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sustained objective response rate in measurable ACP post-surgery without prior radiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of anal lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: sTn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 12-Month Viral Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of minimal residual disease negativity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enjoyment
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: In-Session Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in serum prealbumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of subjects with modified Rankin scale score ≤ 1
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percent agreement of the diagnosis by psychiatrist and AI - SPs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent agreement of the diagnosis by psychiatrist and AI - Patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Modified Rankin Scale (mRS) at 1 year
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Severe complication (Clavien Dindo ≥ 3)
Endpoint domain: Adverse events/effects
Primary endpoint: Ileal intubation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Ileal intubation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Retention rate at the end of treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Retention rate at 3-months follow up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in symptoms of CPTSD on the International Trauma Questionnaire (ITQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline blepharospasm evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Average Number of Weekly Number of Spontaneous Bowel Movements (SBMs) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Efficacy of steroids compared to Avocado Oil Cream
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of steroids compared to Avocado Oil Cream
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in EASI scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in BSA% scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in IsGA scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Color matching accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients reporting an adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Level of inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Child Body Mass Index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Asthma Control Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Asthma and Obesity Specific Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Heart-carotid pulse wave velocity (hcPWV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean estimated glomerular filtration rate (eGFR) at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage correctly diagnosed cystic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of VMB-100 injection, pain
Endpoint domain: Adverse events/effects
Primary endpoint: Vital signs following VMB-100 administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-lead ECG following VMB-100 administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Working memory accuracy under interference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Theta-gamma cross-frequency coupling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fronto-parietal theta phase synchronization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in weight for the for-age z score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nature of final diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to recruitment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participant Adherence to Protocol
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Corneal haze/scarring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake of prenatal genetic testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: number of prescriptions concerned by rules
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Moderate to severe adverse event occurrences
Endpoint domain: Adverse events/effects
Primary endpoint: Survival with native liver at 24 weeks post treatment
Endpoint domain: Mortality/survival
Primary endpoint: a pressure-pain threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity of NeoTIL-ACT
Endpoint domain: Adverse events/effects
Primary endpoint: Level of serum cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Level of dehydroepiandrosterone (DHEA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cmax of CKD-331
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt of CKD-331
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with interventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Physical observation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in baseline number of AKs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of participants with a positive tetanus response at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of participants with a positive pneumococcal vaccine response at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ulcer depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from device- and procedure-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: 30 days clinically driven target vessel revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: GLUSENTIC index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The risk of sarcopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in health status measure for low back pain at 2-month
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in health status measure for low back pain at 6-month
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Determination of Recommended Phase II dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion with treatment failure of allocated respiratory support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum observed drug concentration (Cmax) of AZD4041
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under concentration-time curve from time 0 to infinity (AUCinf) of AZD4041
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Self-reported withdrawal symptoms measured by the Short Opioid Withdrawal Scale-Gossop (SOWS-G)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant Changes From Baseline in Renal Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants with Clinically Significant Changes from Baseline in Transaminases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total nighttime sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Intracranial Overall Response Rate (iORR)
Endpoint domain: Mortality/survival
Primary endpoint: Intracranial Median Progression Free Survival (iPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Dose coverage of target volume (V100%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance rate of NICU WECS and WECS Training
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Posttraumatic Stress Disorder Checklist, Civilian Version DSM-5 (PCL-5)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Heavy Episodic Drinking (HED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily Drinking Questionnaire (DDQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes